Statins in the prevention and management of prostate cancer: an update

A recent review article in the journal Nature Reviews: Urology has concluded that, while we are learning a lot more about the potential role(s) of statins in the prevention and management of prostate cancer, we still have no definitive evidence of their value. … READ MORE …

Time from diagnosis to initiation of primary radiation therapy: does it effect outcomes?

Patients are often concerned about delaying initiation of treatment. Will it give the cancer a chance to metastasize? What if the random biopsy didn’t detect existing higher grade cancer? This is particularly of concern to patients considering active surveillance. … READ MORE …

An update on the shortage of radium-223 (Xofigo)

On October 21, here in the USA, Bayer HealthCare Pharmaceuticals issued a Dear Healthcare Professional letter to medical professionals indicating that the company still does not know when it is likely to be able to start to re-supply this radiopharmaceutical agent for the treatment of late-stage prostate cancer. … READ MORE …

Delaying onset of erectile dysfunction when receiving radiation therapy

Daily treatment with sildenafil citrate (Viagra) seems to have been able to help maintain erectile function for up to 2 years among men receiving such adjuvant treatment during and after radiotherapy for localized prostate cancer. … READ MORE …

Delaying surgery for localized prostate cancer … what’s the downside?

A paper published in June this year in the Journal of Sexual Medicine suggests that delaying radical prostatectomy (RP) as a first-line treatment for localized prostate cancer has no significant effects on post-surgical pathology or mortality but may lead to higher risk for incontinence and erectile dysfunction. … READ MORE …

The proposed REALITY trial and the impact of statins on prostate cancer

As a mentioned earlier this week, a new article by Moyad and Klotz has suggested that it may be possible to carry out a randomized clinical trial to evaluate the impact of statin therapy on the progression of early stage prostate cancer. … READ MORE …

Impact of denosumab on bone metastasis-free survival

A presentation at the American Urological Association annual meeting in Washington a few days ago provided data that treatment with denosumab (Xgeva) delayed the onset of bone metastasis by 4.2 months compared to treatment with a placebo in men with high-risk, non-metastatic, castration-resistant prostate cancer. … READ MORE …

Delayed follow-up care of men with a high PSA found to be common

For any man with a first-time PSA level > 10 ng/ml, there is significant risk for prostate cancer, and early follow-up care — including a repeat PSA test and potentially a biopsy — is probably a priority unless the patient has a life expectancy of 10 years or less. … READ MORE …

Denosumab delays onset of bone mets in men with CRPC

According to a media release, issued late yesterday by Amgen, treatment with denosumab can significantly improve bone metastasis-free survival compared to treatment with a placebo in men with castrate-resistant prostate cancer (CRPC), a rising PSA, but no evidence of bone metastases. … READ MORE …